XML 31 R18.htm IDEA: XBRL DOCUMENT
v3.22.0.1

Business Segments | 6 Months Ended
--- | ---
Dec. 31, 2021
Business Segments |
Business Segments | 10. Business Segments We evaluate performance and allocate resources, based on the Animal Health, Mineral Nutrition and Performance Products segments. Certain of our costs and assets are not directly attributable to these segments and we refer to these items as Corporate. We do not allocate Corporate costs or assets to the segments because they are not used to evaluate the segments’ operating results or financial position. Corporate costs include certain costs related to executive management, business technology, legal, finance, human resources and business development. We evaluate performance of our segments based on Adjusted EBITDA. We define Adjusted EBITDA as income before income taxes plus (a) interest expense, net, (b) depreciation and amortization, (c) (income) loss from, and disposal of, discontinued operations, and (d) other expense or less other income, as separately reported on our consolidated statements of operations, including foreign currency (gains) losses, net and certain items that we consider to be unusual, non-operational or non-recurring. The accounting policies of our segments are the same as those described in the summary of significant accounting policies included herein. ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | Three Months |  | Six Months |
For the Periods Ended December 31 |  | 2021 |  | 2020 |  | 2021 |  | 2020 | ​
Net sales |  |  |  |  |  |  |  |  |  |  |  |  |
Animal Health | ​ | $ | 150,927 | ​ | $ | 136,238 | ​ | $ | 291,931 | ​ | $ | 264,607 | ​
Mineral Nutrition | ​ |  | 66,655 | ​ |  | 54,157 | ​ |  | 121,087 | ​ |  | 105,597 | ​
Performance Products | ​ |  | 15,130 | ​ |  | 15,754 | ​ |  | 34,359 | ​ |  | 31,139 | ​
Total segments | ​ | $ | 232,712 | ​ | $ | 206,149 | ​ | $ | 447,377 | ​ | $ | 401,343 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Depreciation and amortization | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Animal Health | ​ | $ | 6,517 | ​ | $ | 6,498 | ​ | $ | 12,937 | ​ | $ | 13,019 | ​
Mineral Nutrition | ​ |  | 660 | ​ |  | 747 | ​ |  | 1,299 | ​ |  | 1,396 | ​
Performance Products | ​ |  | 437 | ​ |  | 423 | ​ |  | 856 | ​ |  | 868 | ​
Total segments | ​ | $ | 7,614 | ​ | $ | 7,668 | ​ | $ | 15,092 | ​ | $ | 15,283 | ​
Adjusted EBITDA | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Animal Health | ​ | $ | 33,696 | ​ | $ | 33,349 | ​ | $ | 61,333 | ​ | $ | 63,450 | ​
Mineral Nutrition | ​ |  | 5,525 | ​ |  | 4,185 | ​ |  | 10,058 | ​ |  | 7,232 | ​
Performance Products | ​ |  | 1,324 | ​ |  | 2,266 | ​ |  | 3,462 | ​ |  | 4,238 | ​
Total segments | ​ | $ | 40,545 | ​ | $ | 39,800 | ​ | $ | 74,853 | ​ | $ | 74,920 | ​
Reconciliation of income before income taxes to Adjusted EBITDA | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Income before income taxes | ​ | $ | 23,530 | ​ | $ | 16,052 | ​ | $ | 33,125 | ​ | $ | 32,561 | ​
Interest expense, net | ​ |  | 2,953 | ​ |  | 3,214 | ​ |  | 5,842 | ​ |  | 6,024 | ​
Depreciation and amortization – Total segments | ​ |  | 7,614 | ​ |  | 7,668 | ​ |  | 15,092 | ​ |  | 15,283 | ​
Depreciation and amortization – Corporate | ​ |  | 387 | ​ |  | 420 | ​ |  | 763 | ​ |  | 841 | ​
Corporate costs | ​ | ​ | 11,453 | ​ | ​ | 11,258 | ​ | ​ | 23,295 | ​ | ​ | 22,089 | ​
Gain on sale of investment | ​ | ​ | (1,203) | ​ | ​ | — | ​ | ​ | (1,203) | ​ | ​ | — | ​
Stock-based compensation | ​ |  | — | ​ |  | 564 | ​ |  | — | ​ |  | 1,129 | ​
Foreign currency (gains) losses, net | ​ |  | (4,189) | ​ |  | 624 | ​ |  | (2,061) | ​ |  | (3,007) | ​
Adjusted EBITDA – Total segments | ​ | $ | 40,545 | ​ | $ | 39,800 | ​ | $ | 74,853 | ​ | $ | 74,920 | ​
​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | December 31, |  | June 30,
As of |  | 2021 |  | 2021
Identifiable assets |  | ​ |  |  | ​ |
Animal Health | ​ | $ | 589,809 | ​ | $ | 595,315
Mineral Nutrition | ​ |  | 77,122 | ​ |  | 67,338
Performance Products | ​ |  | 38,099 | ​ |  | 36,847
Total segments | ​ |  | 705,030 | ​ |  | 699,500
Corporate | ​ |  | 143,928 | ​ |  | 141,825
Total | ​ | $ | 848,958 | ​ | $ | 841,325
​ The Animal Health segment includes all goodwill of the Company. Corporate assets include cash and cash equivalents, short-term investments, debt issuance costs, income tax-related assets and certain other assets.

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 34 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 26 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 15 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -URI http://asc.fasb.org/topic&trid=2134510 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration